Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
This study is currently recruiting patients.
Sponsored by: |
Memorial Sloan-Kettering Cancer Center
|
Information provided by: |
National Cancer Institute (NCI) |
Purpose
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.
PURPOSE: Phase I trial to study the effectiveness of intravenous VEGF Trap in treating patients who have relapsed or refractory
advanced solid tumors or non-Hodgkin's lymphoma.
Condition
|
Treatment or Intervention |
Phase |
Cancer
|
Drug: VEGF Trap Procedure: anti-cytokine therapy Procedure: antiangiogenesis therapy Procedure: biological response modifier therapy Procedure: growth factor antagonist therapy Procedure: targeted fusion protein therapy
|
Phase I
|
MedlinePlus related topics: Cancer; Cancer Alternative Therapy
Study Type: Interventional
Study Design: Treatment
Official Title: Phase I Study of Intravenous VEGF Trap in Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Further Study Details:
OBJECTIVES: Primary
- Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed or refractory advanced solid tumors
or non-Hodgkin's lymphoma.
Secondary
- Determine the maximum tolerated intravenous dose of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
- Determine the ability of this drug to bind circulating vascular endothelial growth factor in these patients.
- Determine, preliminarily, the ability of this drug to alter tumor blood flow and tumor vascular permeability in these patients.
- Determine whether antibodies to this drug develop in these patients.
OUTLINE: This is an open-label, dose-escalation, multicenter study.
Patients receive VEGF Trap IV over 1 hour on days 1 and 15 for a total of 2 doses.
Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD
is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined,
an additional 6 patients are treated at that dose level.
In the absence of dose-limiting toxicity, patients with stable disease or partial or complete remission may continue to receive
VEGF Trap on a separate extension protocol.
Patients are followed at weeks 1, 3, and 7 and then at 3 months.
PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study.
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
DISEASE CHARACTERISTICS:
- Histologically confirmed diagnosis of one of the following:
- Non-Hodgkin's lymphoma
- Primary or metastatic solid tumor located, by radiography, in at least one of the following sites:
- Liver
- Soft tissue
- Pelvis
- Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)
- Relapsed or refractory (including unresectable) disease
- Patients with solid tumors must have failed all curative chemotherapeutic regimens
- Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
- Not amenable to available conventional therapies AND no standard therapy exists
- Measurable disease
- No prior or concurrent CNS metastases (brain or leptomeningeal)
- No primary intracranial tumor by MRI or CT scan
- No histologically confirmed squamous cell carcinoma of the lung
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
- WBC ≥ 3,500/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 100,000/mm^3
- No severe or uncontrolled hematologic condition
Hepatic
- Bilirubin ≤1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- PT and PTT normal
- INR normal
- Hepatitis B surface antigen negative
- Hepatitis C antibody negative
Renal
- Creatinine ≤ ULN
- Urine protein/creatinine ratio ≤ 1
- No severe or uncontrolled renal condition
Cardiovascular
- No clinically significant acute electrocardiographic abnormalities
- LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines
- No untreated or uncontrolled hypertension
- No blood pressure > 150/100 mm Hg (despite treatment)
- No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at least 2 determinations [on separate days]
within the past 3 months)
- No New York Heart Association class II - IV heart disease
- No active coronary artery disease requiring acute medical management
- No angina requiring acute medical management
- No congestive heart failure requiring acute medical management
- No ventricular arrhythmia requiring acute medical management
- No stroke or transient ischemic event within the past 6 months
- No prior or concurrent peripheral vascular disease
- No angiographically or ultrasonographically documented arterial or venous occlusive event
- No symptomatic claudication
- No symptomatic orthostatic hypotension
- No other severe or uncontrolled cardiovascular condition
Pulmonary
- No severe or uncontrolled pulmonary condition
- No pulmonary embolism within the past 6 months
Immunologic
- HIV negative
- No severe or uncontrolled immunologic condition
- No active current infection requiring antibiotics
- No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap
Other
- No severe or uncontrolled gastrointestinal or musculoskeletal condition
- No psychiatric condition or adverse social circumstance that would preclude study participation
- No other condition that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment
PRIOR CONCURRENT THERAPY: Biologic therapy
- See Disease Characteristics
- No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial
- At least 3 weeks since prior immunotherapy and recovered
- No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)
Chemotherapy
- See Disease Characteristics
- At least 3 weeks since prior chemotherapy and recovered
Endocrine therapy
- No concurrent adrenal corticosteroids except low-dose replacement therapy
- No concurrent systemic hormonal contraceptive agents
Radiotherapy
- At least 3 weeks since prior radiotherapy and recovered
Surgery
- At least 3 weeks since prior major or laparoscopic surgery and recovered
- More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral
ischemic events
Other
- More than 30 days since prior investigational drugs
- No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin
for maintaining patency of venous access devices
- No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
- No other concurrent anticancer investigational agents
- No other concurrent anticancer therapy
Location
and Contact
Information
New York Memorial Sloan-Kettering Cancer Center, New York,
New York,
10021,
United States; Recruiting
David R. Spriggs, MD
212-639-2203
Study chairs or principal investigators
Jakob Dupont, MD, Principal Investigator, Memorial Sloan-Kettering Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers:
CDR0000360856; MSKCC-03137; REGENERON-VGFT-ST-0202
Record last reviewed:
August 2004
Record first received:
May 14, 2004
ClinicalTrials.gov Identifier:
NCT00083213Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-11-17